Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $31.4800 (-0.03%) ($31.4800 - $31.4800) on Fri. Oct. 8, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.6% (three month average) | RSI | 54 | Latest Price | $31.4800(-0.03%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.2% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(69%) ARKG(65%) IBB(61%) ARKK(60%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -2.3% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-19%) UNG(-6%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.3% (StdDev 4.6%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $31.76 | 5 Day Moving Average | $31.75(-0.85%) | 10 Day Moving Average | $32.61(-3.47%) | 20 Day Moving Average | $31.76(-0.88%) | To recent high | -21.8% | To recent low | 45.2% | Market Cap | $3.987b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |